Sugi Predict

Sugi Predict / Compounds / SCHEMBL9866677

SCHEMBL9866677

SCHEMBL9866677

Nc1ccc([N+](=O)[O-])c2c1C(=O)CCC2

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 7/20 0.43
▸ POLB P06746 2/20 0.42
▸ APEX1 P27695 1/20 0.42
▸ CASP6 P55212 1/20 0.42
▸ CTDSP1 Q9GZU7 1/20 0.42
▸ MAPT P10636 4/20 0.40
▸ CYP3A4 P08684 3/20 0.40
▸ TSHR P16473 3/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ LMNA P02545 1/20 0.39
▸ GAA P10253 1/20 0.38
▸ BRD4 O60885 1/20 0.37
▸ GPR35 Q9HC97 1/20 0.37
▸ GFER P55789 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ SIRT6 Q8N6T7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22463118 0.87 TDP1 (0.40) TDP1POLBAPEX1CASP6CTDSP1
SCHEMBL4657132 0.85 TSHR (0.42) TDP1MAPTCYP3A4TSHRALDH1A1
SCHEMBL4656524 0.81 MAPT (0.46) TDP1POLBMAPTTSHRALDH1A1
SCHEMBL22463115 0.79 BRD4 (0.44) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL4659309 0.78 HPGD (0.39) MAPTCYP3A4ALDH1A1MEN1KMT2A
SCHEMBL7117117 0.78 TDP1 (0.50) TDP1POLBAPEX1CASP6CTDSP1
SCHEMBL31177224 0.77 TP53 (0.53) POLBAPEX1CASP6MAPTCYP3A4
SCHEMBL9404841 0.77 TP53 (0.53) POLBAPEX1CASP6MAPTCYP3A4
SCHEMBL7102164 0.77 ALDH1A1 (0.53) TDP1MAPTALDH1A1MEN1KMT2A
Hydrochloric Acid SCHEMBL9868389 0.77 BRD4 (0.43) MAPTALDH1A1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051463-A1 CD123 ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THE SAME ASTRAZENECA AB (SE) 2025-02-13 — — US disclosed
WO-2025027472-A2 CD123 ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THE SAME ASTRAZENECA AB (SE) 2025-02-06 — — WO disclosed
CN-117263948-B Compounds and conjugates thereof 免疫医疗有限公司 2024-11-22 — — CN disclosed
US-20240239894-A1 THERAPEUTIC BINDING MOLECULES MEDIMMUNE LIMITED (GB) 2024-07-18 — — US disclosed
US-20240239894-A1 THERAPEUTIC BINDING MOLECULES MEDIMMUNE LIMITED (GB) 2024-07-18 — — US disclosed
CN-118240003-A Compounds and conjugates thereof 免疫医疗有限公司 2024-06-25 — — CN disclosed
CN-118221763-A Compounds and conjugates thereof 免疫医疗有限公司 2024-06-21 — — CN disclosed
CN-113631196-B Compounds and conjugates thereof 免疫医疗有限公司 2024-03-15 — — CN disclosed
CN-117263948-A Compounds and conjugates thereof 免疫医疗有限公司 2023-12-22 — — CN disclosed
US-11795225-B2 Therapeutic binding molecules MEDIMMUNE LIMITED (GB) 2023-10-24 — — US disclosed
US-20220211863-A1 COMPOUNDS AND CONJUGATES THEREOF MEDIMMUNE LIMITED (GB) 2022-07-07 — — US disclosed
US-20220098308-A1 THERAPEUTIC BINDING MOLECULES MEDIMMUNE LIMITED (GB) 2022-03-31 — — US disclosed
WO-2022053650-A1 THERAPEUTIC B7-H4 BINDING MOLECULES MEDIMMUNE LIMITED (GB) 2022-03-17 — — WO disclosed
EP-3946464-A1 COMPOUNDS AND CONJUGATES THEREOF MedImmune Limited (GB) 2022-02-09 — — EP disclosed
CN-113631196-A Compounds and conjugates thereof 免疫医疗有限公司 2021-11-09 — — CN disclosed
US-20210322401-A1 COMPOUNDS AND CONJUGATES THEREOF MEDIMMUNE LIMITED (GB) 2021-10-21 — — US disclosed
WO-2021148500-A1 COMPOUNDS AND CONJUGATES THEREOF MEDIMMUNE LIMITED (GB) 2021-07-29 — — WO disclosed
WO-2020200880-A1 COMPOUNDS AND CONJUGATES THEREOF MEDIMMUNE LIMITED (GB) 2020-10-08 — — WO disclosed
US-20200306243-A1 COMPOUNDS AND CONJUGATES THEREOF MEDIMMUNE LIMITED (GB) 2020-10-01 — — US disclosed
US-5061795-A ANTITUMOR AGENTS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1991-10-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220211863-A1 COMPOUNDS AND CONJUGATES THEREOF TOP2A, TOP1, TOP2B TDP1 38/4885POLB 169/4885APEX1 227/4885
US-11795225-B2 Therapeutic binding molecules EPCAM, IGSF11, FCGR3B TDP1 4144/4885POLB 3098/4885APEX1 1899/4885
US-20200306243-A1 COMPOUNDS AND CONJUGATES THEREOF TOP2A, TOP1, TOP2B TDP1 38/4885POLB 169/4885APEX1 227/4885
US-20240239894-A1 THERAPEUTIC BINDING MOLECULES EPCAM, IGSF11, FCGR3B TDP1 4144/4885POLB 3098/4885APEX1 1899/4885
US-20250051463-A1 CD123 ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THE SAME IL23R, CD63, CD2 TDP1 782/4885POLB 2886/4885APEX1 1835/4885
US-20210322401-A1 COMPOUNDS AND CONJUGATES THEREOF TOP2A, TOP1, TOP2B TDP1 38/4885POLB 169/4885APEX1 227/4885
US-20220098308-A1 THERAPEUTIC BINDING MOLECULES EPCAM, IGSF11, FCGR3B TDP1 4144/4885POLB 3098/4885APEX1 1899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.